FTX-6746 is an orally active PPARG inhibitor. FTX-6746 shows potent tumor inhibition in mouse xenograft models.
FTX-6746 (3-60 mg/kg; po; twice daily for 21 d) results significant tumor suppression in UMUC9 or HT1197 xenograft model in mouse[1].
References:
[1]. Mertz J, et al. Novel inhibitors of the luminal lineage transcription factor peroxisome proliferator-activated receptor gamma (PPARG) durably eradicate tumors in urothelial cancer (UC) animal models[J]. European Journal of Cancer, 2022, 174: S33-S34.
















